32 results about "Corilagin" patented technology

The invention discloses the application of corilagin in inhibiting the replication of coronavirus so as to exert the function of anti-coronavirus drug. Corilagin, the CAS number is 23094‑69‑1, the Chinese name is Corilagin, the English name is Corilagin, and the structural formula is shown in formula (I). The present invention provides the application of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is the following (a) or (b): (a) in the preparation of coronavirus inhibitors; (b) in Inhibition of coronavirus applications. The present invention proves through experiments that the compound represented by formula (I) can effectively inhibit the replication of SARS-CoV-2 in vitro, has good anti-SARS-CoV-2 activity, and has important application prospects for treating SARS-CoV-2 infection.

The invention relates to novel application of corilagin or a pharmaceutically acceptable corilagin salt, in particular to application of the corilagin or the pharmaceutically acceptable corilagin salt in treating or preventing diseases related to gastric acid hypersecretion such as hyperchlorhydria, peptic ulcer and chronic gastritis.

The invention discloses an extraction-separation method and an application of corilagin. The method comprises the steps of treating longan kernel powder once by using anhydrous acetone and extracting by using acetone aqueous solution again for the second time; uniformly mixing a proper amount of chromatography polyamide with the acetone aqueous solution, recycling acetone and applying to a polyamide chromatography column; eluting by sequentially using pure water, methyl alcohol aqueous solutions with different concentrations and methyl alcohol; gathering 40-60 percent of methyl alcohol eluant in a separate bottle form, condensing and separating out corilagin crystals; mixing mother liquid with the rest of eluant containing corilagin, condensing to be dry, dissolving into methyl alcohol and applying to a polydextran gel LH-20 column; eluting by methyl alcohol; gathering eluant in a separate bottle form and standing; mixing with the eluants in which corilagin crystals are separated out; standing again until the orilagin crystals which are separated out are not increased; mixing the obtained corilagin crystals with corilagin crystals obtained by chromatography polyamide; performing recrystallization by using ethyl alcohol to obtain corilagin with high purity. The corilagin subjected to extraction and separation has a function of inhibiting tyrosinase.

The present invention relates to the new application of Corilagin in the preparation of sleep deprivation medicine. The mouse sleep model was established by using the small platform water environment method, and the Morris maze / platform experiment was carried out to investigate the learning and memory ability, and further detected the oxidoreductase and cholinergic indicators of the hippocampal tissue. The results showed that the administration of corilagin significantly improved the behavioral disorders of sleep-deprived mice, relieved the oxidative stress damage of hippocampus tissue, and strengthened the cholinergic system. It is suggested that Corilagin can significantly improve the behavior of sleep-deprived mice, and has a certain application prospect in coping with high-intensity continuous operations.

The invention belongs to the technical field of pharmaceutic preparations containing algae, moss, fungi or plants or derivatives thereof, for example, uncertain structures of traditional herbs, and discloses a Chinese herbal medicinal ingredient prescription capable of improving swine immunosuppression and a preparation method and application of the Chinese herbal medicinal ingredient prescription. The mass ratio of corilagin, cordycepin, icariin and peoniflorin is 1-4: 1-4: 1-4: 1-4. The corilagin, the cordycepin, the icariin and the peoniflorin are added with normal saline to prepare liquidmedicine with the total concentration being 2 mg / mL according to the mass ratio of 1-4: 1-4: 1-4: 1-4. The specific antibody titer of animals can be improved effectively, the viral load is reduced, the number and activity of immunocytes and immunotransmitters are increased, growth and development of immune organs are promoted, the immunologic function and the disease resistance of the animal can be enhanced comprehensively, toxic and side effects of vaccines, chemical drugs and antibiotics and potential safety hazards of food are overcome, the research and development prospect is promising, and clinical application is wide.

The invention discloses the use of corilagin in the preparation of anti-myocardial fibrosis medicine. It belongs to the technical field of biomedicine. The present invention conducts experimental research by constructing an in vivo myocardial fibrosis model caused by mouse aortic ligation and an in vitro myocardial fibrosis model of rat suckling rat CFs induced by TGF-β, and the results show that corilagin can regulate the polarization of macrophages Thereby inhibiting inflammation, while down-regulating IL-4 receptors to avoid excessive production of TGF-β, and reducing the activation of myocardial fibroblasts by inhibiting the expression of TGF-β receptors, thereby reducing collagen content and reducing myocardial fibrosis. The present invention proposes that corilagin can reduce myocardial fibrosis caused by long-term pressure load, protect heart tissue, inhibit or delay the deterioration of cardiac function, has a significant effect in anti-myocardial fibrosis, and has few side effects, and can be used to prepare anti-myocardial fibrosis drugs .